Biotechnology company Rakuten Medical Inc announced on Monday that it has initiated a Phase 1 clinical trial of RM-0256 photoimmunotherapy in Japan.
RM-0256, an anti-PD-L1 antibody-light-activatable dye conjugate, is the third drug candidate developed by Rakuten Medical based on its Alluminox platform.
The first-in-human, open-label, non-controlled, dose-escalation trial will enrol 24 patients with solid tumours, including malignant skin tumours, who are refractory to or ineligible for standard treatment. It is funded by the Japan Agency for Medical Research and Development (AMED) to support the development of RM-0256 for advanced or recurrent malignant epithelial skin tumours, which are the initial target indication in this study.
The primary objectives of the study are to evaluate the safety and tolerability of RM-0256 photoimmunotherapy and to identify recommended drug and light doses for Phase 2 clinical development. Primary endpoints include dose-limiting toxicities and adverse events. Secondary endpoints include tumour response and pharmacokinetic parameters of RM-0256. Exploratory assessments will also evaluate biomarkers associated with RM-0256 photoimmunotherapy.
The Alluminox platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies.
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Abbott reports 30-day results from clinical trial of SonicForce Coronary IVL System
Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system
VibroSense Dynamics secures Thai regulatory approval for VibroSense Meter II
SciBase technology selected as primary endpoint in NIH-led skin exposure study
FDA approves Vantis Vascular's 6F CrossFAST model
TWINBIRD launches portable freezer targeting dry-ice-free research cold chains
Urolution Medical secures FDA clearance for OpenFlo urinary catheter
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
Okami Medical receives FDA approval for expanded indication of LOBO Vascular Occluder
Oxurion in talks to acquire Eclevar's MedTech CRO business and assets
FDA Advisory Committee votes in favour of GRAIL's Galleri multi-cancer early detection test